News & Insights

Dec 15, 2021

Unlocking the potential of the NLRP3 inflammasome to treat chronic inflammatory diseases

NodThera is developing a portfolio of novel, potent and selective NLRP3 inflammasome inhibitors, with one clinical-stage candidate and several others in preclinical development. The company is seeking partners to advance its programs through clinical development in a range of indications.

Read more